Research and Markets (http://www.researchandmarkets.com/research/e2c21e/rethinking_pharmac) has announced the addition of Decision Resources, Inc.'s new report "Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?" to their offering.
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses and finding creative ways to partner with biotech companies and with each other to access or acquire promising technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations, generics competition, and other industry pressures.
Questions Answered in This Report
In recent years, drug developers have invested heavily in various R&D technologies.
- Is this investment increasing R&D productivity?
- What technology strategies are most promising?
- What new approaches are pharmaceutical companies using to access enabling technologies for drug discovery?
Pharmaceutical companies are seeking to reinvigorate R&D organizations to improve productivity.
- What steps are leading companies taking to change R&D?
- What structures and strategies have already been implemented within Big Pharma R&D organizations?
- Can pharmaceutical companies replicate the innovation of biotech companies by reforming R&D?
Biotech companies are an important source of novel technologies and drug candidates.
- How do acquisitions of and collaborations with biotech companies fit into Big Pharma's R&D strategies?
- How can companies use business development activities to build up technological capabilities and pipelines?
Several Big Pharma companies are charting new territory in early-stage pharma-pharma dealmaking.